Atrial fibrillation Study Guide

📖 Core Concepts Atrial fibrillation (AF) – a supraventricular tachycardia with rapid, irregular atrial activity; ventricular response is irregular (“irregularly irregular”). Electrical trigger – ectopic beats, most often from the pulmonary‑vein (PV) ostia, that overwhelm the sinus node. Structural substrate – atrial dilation & fibrosis (driven by hypertension, valve disease, inflammation) that stabilizes re‑entrant circuits/rotors. Rate vs. Rhythm control – two therapeutic philosophies: (1) slow ventricular rate to protect hemodynamics, (2) restore sinus rhythm to eliminate AF‑related symptoms. Stroke risk – AF causes blood stasis in the left atrial appendage (LAA) → thrombus → embolic stroke; quantified with the CHA₂DS₂‑VASc score. ABC pathway – Anticoagulation, Better symptom control (rate / rhythm), Cardiovascular risk‑factor management. --- 📌 Must Remember Prevalence: >33 million worldwide; rises sharply with age (0.1 % <50 yr → 14 % >80 yr). Key risk factors: Hypertension, valvular disease, heart failure, CAD, obesity, sleep apnea, alcohol binge, thyroid disorders. ECG hallmark: Absent P waves + irregular R‑R intervals; QRS usually narrow. Classification (temporal): Paroxysmal ≤7 days (usually ≤24 h) Persistent >7 days, needs intervention Long‑standing persistent ≥1 yr Permanent – rhythm not pursued. CHA₂DS₂‑VASc scoring: C = Congestive HF (1) H = Hypertension (1) A₂ = Age ≥75 yr (2) D = Diabetes (1) S₂ = Stroke/TIA/ thrombo‑embolism (2) V = Vascular disease (1) A = Age 65‑74 yr (1) Sc ≥2 → anticoagulation indicated. Anticoagulant hierarchy: DOACs (apixaban, dabigatran, edoxaban, rivaroxaban) preferred over warfarin except in moderate‑to‑severe mitral stenosis or mechanical valve. Rate‑control target: Resting HR <110 bpm (lenient); <80 bpm if LV hypertrophy or HF. First‑line rate drugs: β‑blockers > non‑DHP CCBs > digoxin (elderly, sedentary). Catheter ablation: Pulmonary‑vein isolation; most effective in paroxysmal AF, younger patients, little structural disease. --- 🔄 Key Processes AF Initiation PV ectopic firing → rapid atrial depolarization → irregular AV node conduction → irregular ventricular response. AF Maintenance Atrial dilation → RAAS activation → matrix metalloproteinases → fibrosis → slowed conduction + short refractory periods → re‑entry/rotors. Stroke Prevention Workflow Calculate CHA₂DS₂‑VASc → if ≥2 → start DOAC (adjust for renal function) → monitor adherence; consider LAA occlusion if anticoagulation contraindicated. Rate‑Control Titration Start β‑blocker (e.g., metoprolol 25 mg BID) → assess HR after 48 h → add non‑DHP CCB if needed → consider digoxin if resting HR still >110 bpm and patient is sedentary. Rhythm‑Control Decision Tree Symptomatic + <1 yr onset → consider early rhythm control (anti‑arrhythmic + possible ablation). Structural heart disease + HF → prioritize rate control; reserve rhythm control for refractory symptoms. --- 🔍 Key Comparisons AF vs. Atrial Flutter AF: No discrete P waves, irregular R‑R; chaotic atrial activity. Flutter: Saw‑tooth “F” waves, usually regular atrial rate (300 bpm). DOAC vs. Warfarin DOAC: Fixed dosing, no INR monitoring, lower intracranial bleed, higher intestinal bleed (dabigatran). Warfarin: INR‑targeted (2‑3), requires monitoring, preferred in mechanical valve/mitral stenosis. β‑Blocker vs. Non‑DHP CCB β‑Blocker: Decreases AV nodal conduction, also reduces sympathetic drive (beneficial in HF). Non‑DHP CCB: Primarily AV nodal block, contraindicated in HFrEF. Paroxysmal vs. Persistent AF Paroxysmal: Self‑terminating ≤7 days, higher success with ablation. Persistent: Requires cardioversion/ablation; lower ablation success. --- ⚠️ Common Misunderstandings “Asymptomatic AF doesn’t need anticoagulation.” – Stroke risk is independent of symptoms; CHA₂DS₂‑VASc drives anticoagulation. “Aspirin is sufficient for stroke prevention.” – Aspirin alone (or with clopidogrel) is not recommended; DOACs are superior. “Rate control eliminates the need for anticoagulation.” – Anticoagulation is based on stroke risk, not rhythm strategy. “All AF patients need ablation.” – Ablation is reserved for symptomatic patients who fail/drug‑intolerant or have favorable anatomy. --- 🧠 Mental Models / Intuition “Fire‑starter + Fuel = AF” – PV ectopic beats (fire‑starter) + fibrotic substrate (fuel) → sustained AF. “Irregular pulse = irregular risk” – The more irregular the ventricular response, the higher the chance of hemodynamic compromise and embolic events. “Score → Treat” – Treat every patient whose CHA₂DS₂‑VASc ≥2 with anticoagulation; treat <2 only if other risk factors (e.g., prior stroke). --- 🚩 Exceptions & Edge Cases Mechanical heart valve / moderate‑to‑severe mitral stenosis: Warfarin remains the anticoagulant of choice. Severe renal impairment (eGFR <15 mL/min): Dose‑adjust DOACs or revert to warfarin; some DOACs contraindicated. LAA thrombus on TEE: Cardioversion postponed until ≥3 weeks of therapeutic anticoagulation. High‑intensity exercise in men: May increase AF risk despite overall benefits of moderate activity. --- 📍 When to Use Which Rate control → older patients, HF with reduced EF, minimal symptoms, CHA₂DS₂‑VASc high, or when rhythm control fails. Rhythm control → recent‑onset AF (<1 yr), highly symptomatic, younger, active lifestyle, or HF with preserved EF where symptom relief is needed. DOAC → most non‑valvular AF patients; check renal function, drug‑drug interactions. Warfarin → mechanical valve, moderate‑to‑severe mitral stenosis, or when DOACs are contraindicated. Catheter ablation → symptomatic paroxysmal AF, failed ≥1 anti‑arrhythmic drug, or patient preference for drug‑free rhythm. LAA occlusion → contraindication to long‑term anticoagulation or high bleeding risk. --- 👀 Patterns to Recognize Irregularly irregular pulse on exam → think AF; confirm with ECG. Shortness of breath + rapid irregular rhythm → possible HF decompensation secondary to AF. Stroke/TIA in a patient with no carotid disease → screen for silent AF (Holter, wearable monitor). Elevated jugular venous pressure + pulmonary crackles + AF → look for rapid ventricular response causing HF. --- 🗂️ Exam Traps “Aspirin is adequate for low‑risk AF” – wrong; guideline recommends no antiplatelet monotherapy for stroke prevention. “All patients with AF need rhythm control” – false; rate control is equally effective for many, especially in HF. “A CHA₂DS₂‑VASc of 1 in women always requires anticoagulation” – only if other risk factors present; women get +1 point automatically, but anticoagulation is recommended for score ≥2. “Wide QRS on ECG excludes AF” – wide QRS can coexist with AF if there is bundle‑branch block or ventricular disease; the key is the irregular R‑R interval and absent P waves. “Beta‑blockers are contraindicated in all AF” – incorrect; they are first‑line for rate control, especially in HF. ---